Fosfomycin calcium

This product is a compound preparation, and its components are: each tablet contains 125 mg of fosfomycin calcium and 25 mg of trimethoprim.

1. It has synergistic effect with β-lactams against Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus) and Pseudomonas aeruginosa, and delays the development of drug resistance. 2. It has synergistic effect with aminoglycosides, and delays the development of drug resistance. 3. There is no cross-resistance with other antibiotics. 4. The chance of leukopenia and thrombocytopenia increases when bone marrow suppressants are used in combination with TMP. 5. When dapsone is used in combination with this product, the blood concentration of both drugs can be increased. The increase of the former can increase and aggravate adverse reactions, especially the occurrence of methemoglobinemia. 6. This product should not be used simultaneously with anti-tumor drugs and 2,4-diaminopyrimidine drugs, nor should it be used between courses of treatment with other folic acid antagonists, because it may cause bone marrow aplasia or megaloblastic anemia. 7. When used in combination with rifampicin, TMP clearance can be significantly increased and serum half-life can be shortened. 8. When used in combination with cyclosporine, renal toxicity can be increased. 9. This product can interfere with the hepatic metabolism of phenytoin, increase the half-life (t1/2) of phenytoin by 50%, and reduce its clearance rate. 10. When used in combination with procainamide, it can reduce the renal clearance of procainamide, resulting in an increase in the blood concentration of procainamide and its metabolite NAPA. 11. When used in combination with warfarin, TMP can inhibit the metabolism of the drug and enhance its anticoagulant effect.

This product is a compound preparation, and its components are: each tablet contains 125 mg of fosfomycin calcium and 25 mg of trimethoprim.

1. It has synergistic effect with β-lactams against Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus) and Pseudomonas aeruginosa, and delays the development of drug resistance. 2. It has synergistic effect with aminoglycosides, and delays the development of drug resistance. 3. There is no cross-resistance with other antibiotics. 4. The chance of leukopenia and thrombocytopenia increases when bone marrow suppressants are used in combination with TMP. 5. When dapsone is used in combination with this product, the blood concentration of both drugs can be increased. The increase of the former can increase and aggravate adverse reactions, especially the occurrence of methemoglobinemia. 6. This product should not be used simultaneously with anti-tumor drugs and 2,4-diaminopyrimidine drugs, nor should it be used between courses of treatment with other folic acid antagonists, because it may cause bone marrow aplasia or megaloblastic anemia. 7. When used in combination with rifampicin, TMP clearance can be significantly increased and serum half-life can be shortened. 8. When used in combination with cyclosporine, renal toxicity can be increased. 9. This product can interfere with the hepatic metabolism of phenytoin, increase the half-life (t1/2) of phenytoin by 50%, and reduce its clearance rate. 10. When used in combination with procainamide, it can reduce the renal clearance of procainamide, resulting in an increase in the blood concentration of procainamide and its metabolite NAPA. 11. When used in combination with warfarin, TMP can inhibit the metabolism of the drug and enhance its anticoagulant effect.

1. It has a synergistic effect when used in combination with beta-lactams against Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus) and Pseudomonas aeruginosa. 2. It has a synergistic effect when used in combination with aminoglycosides. 3. There is no cross-resistance with other antibiotics.